RxDoctor Payments DataLook up a doctor →

Andras Perl, MD

Rheumatology · Syracuse, NYNPI 1558393546

Payments from drug & device makers

$1,239,042in general payments, 2019–2025

Across 181 payments — averaging $6845.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$240K
  • Bristol Myers Squibb$203K
  • Amgen$202K
  • Novartis$176K
  • E.r. Squibb & Sons, L.L.C.$94K
  • UCB SA$90K
  • plus $234K from 12 others
$364in research payments, 2019–2025

Across 4 payments — averaging $91.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$364

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,239,042 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$138,662
Medicare patients
99
Services billed
5,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →